Improving the bioremediation of phenolic wastewaters by Trametes versicolor

The successful bioremediation of a phenolic wastewater by Trametes versicolor was found to be dependent on a range of factors including: fungal growth, culture age and activity and enzyme (laccase) production. These aspects were enhanced by the optimisation of the growth medium used and time of addition of the pollutant to the fungal cultures. Different media containing ‘high’ (20 g/L), ‘low’ (2 g/L) and ‘sufficient’ (10 g/L) concentrations of carbon and nitrogen sources were investigated. The medium containing both glucose and peptone at 10 g/L resulted in the highest Growth Related Productivity (the product of specific yield and μ) of laccase (1.46 Units of laccase activity)/gram biomass/day and was used in all further experiments. The use of the guaiacol as an inducer further increased laccase activity 780% without inhibiting growth; similarly the phenolic effluent studied boosted activity almost 5 times. The timing of the addition of the phenolic effluent was found to have important consequences in its removal and at least 8 days of prior growth was required. Under these conditions, 0.125 g phenol/g biomass and 0.231 g o-cresol/g biomass were removed from solution per day

An acid-stable laccase from sclerotium rolfsii with potential for wool dye decolourization

The plant pathogen basidiomycete S. rolfsii secretes two laccases (SRL1 and SRL2) with molecular weights of 55 and 86 kDa, respectively. Laccase production was shown to be inducible by the addition of 2,5-xylidine to the cultural media. After treatment with a combination of chitinase and -1,3-glucanase, two different laccases were isolated from the sclerotia depending on the stage of sclerotia development. The more prominent laccase, SRL1, was purified and found to decolourize the industrially important wool azo dye Diamond Black PV 200 without the addition of redox mediators. The enzyme (pI 5.2) was active in the acidic pH range, showing an optimal activity at pH 2.4, with ABTS as substrate. The optimum temperature for activity was determined to be 62 ◦C. Enzyme stability studies revealed that SRL1 was notably stable at 18 ◦C and pH 4.5, retaining almost full activity after a week. Oxidation of tyrosine was not detectable under the reaction conditions but the enzyme did oxidize a variety of the usual laccase substrates. SRL1 was strongly inhibited by sodium azide and fluoride. Dye solutions decolourized with the immobilized laccase were successfully used for redyeing.(undefined

Chromosome 3 Anomalies Investigated by Genome Wide SNP Analysis of Benign, Low Malignant Potential and Low Grade Ovarian Serous Tumours

Ovarian carcinomas exhibit extensive heterogeneity, and their etiology remains unknown. Histological and genetic evidence has led to the proposal that low grade ovarian serous carcinomas (LGOSC) have a different etiology than high grade carcinomas (HGOSC), arising from serous tumours of low malignant potential (LMP). Common regions of chromosome (chr) 3 loss have been observed in all types of serous ovarian tumours, including benign, suggesting that these regions contain genes important in the development of all ovarian serous carcinomas. A high-density genome-wide genotyping bead array technology, which assayed >600,000 markers, was applied to a panel of serous benign and LMP tumours and a small set of LGOSC, to characterize somatic events associated with the most indolent forms of ovarian disease. The genomic patterns inferred were related to TP53, KRAS and BRAF mutations. An increasing frequency of genomic anomalies was observed with pathology of disease: 3/22 (13.6%) benign cases, 40/53 (75.5%) LMP cases and 10/11 (90.9%) LGOSC cases. Low frequencies of chr3 anomalies occurred in all tumour types. Runs of homozygosity were most commonly observed on chr3, with the 3p12-p11 candidate tumour suppressor region the most frequently homozygous region in the genome. An LMP harboured a homozygous deletion on chr6 which created a GOPC-ROS1 fusion gene, previously reported as oncogenic in other cancer types. Somatic TP53, KRAS and BRAF mutations were not observed in benign tumours. KRAS-mutation positive LMP cases displayed significantly more chromosomal aberrations than BRAF-mutation positive or KRAS and BRAF mutation negative cases. Gain of 12p, which harbours the KRAS gene, was particularly evident. A pathology review reclassified all TP53-mutation positive LGOSC cases, some of which acquired a HGOSC status. Taken together, our results support the view that LGOSC could arise from serous benign and LMP tumours, but does not exclude the possibility that HGOSC may derive from LMP tumours

Prévention des fractures ostéoporotiques en soins de longue durée. L’utilisation de la médication est-elle pertinente pour tous les patients ?

Résumé : Objectifs : Revoir les données probantes de la littérature médicale concernant l’utilisation des biphosphonates, du calcium et de la vitamine D pour les personnes âgées. Proposer des lignes de conduite pour aider le clinicien dans la gestion des médicaments à visée préventive dans un contexte de soins de longue durée. Sources des données et sélection des études : Une revue de la littérature médicale a été effectuée dans la base de données Pubmed et Cochrane avec les termes nursing home, soins prolongés, ostéoporose, alendronate, risédronate, calcium, vitamin D et insuffisance rénale. Analyse des données : L’utilisation du calcium en combinaison avec la vitamine D a démontré une diminution des fractures chez les résidents ambulants, admis en soins de longue durée. Toutefois, l’utilisation de la vitamine D seule n’a pas permis de démontrer un tel effet. L’utilisation des biphosphonates permet de diminuer la fréquence des fractures chez des patients mobiles admis en hébergement de longue durée et semble sans danger. Certaines données laissent entendre que l’utilisation des biphosphonates chez les patients atteints d’insuffisance rénale sévère présente peu de danger. Conclusion : De plus en plus de données sont disponibles sur l’utilisation de médicaments pour prévenir les fractures associées à l’ostéoporose dans un contexte de soins de longue durée. Toutefois, plusieurs questions demeurent sans réponse. Les facteurs de risques de fracture, l’espérance de vie et les objectifs thérapeutiques doivent être pris en considération lors de la prescription de médicaments visant à prévenir les fractures associées à l’ostéoporose.